73 related articles for article (PubMed ID: 9132749)
1. [Effectiveness and hematotoxicity of paclitaxel monotherapy in patients with advanced non-small cell bronchial carcinoma (NSCLC)].
Leutz M; Schlimmer P; Zell L; Ukena D; Sybrecht G
Pneumologie; 1997 Jan; 51(1):62-5. PubMed ID: 9132749
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Gatzemeier U; Heckmayer M; Neuhauss R; Schlüter I; von Pawel J; Wagner H; Dreps A
Semin Oncol; 1995 Dec; 22(6 Suppl 15):24-8. PubMed ID: 8643966
[TBL] [Abstract][Full Text] [Related]
3. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
[TBL] [Abstract][Full Text] [Related]
9. Preliminary results of a phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
Sørensen JB; Wedervang K; Dombernowsky P
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-18-S12-20. PubMed ID: 9331114
[TBL] [Abstract][Full Text] [Related]
10. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
11. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
12. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
13. Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy.
Juan O; Albert A; Villarroya T; Sánchez R; Casan R; Caranana V; Campos JM; Alberola V
Neoplasma; 2003; 50(3):204-9. PubMed ID: 12937854
[TBL] [Abstract][Full Text] [Related]
14. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
15. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials.
DeVore RF; Jagasia M; Johnson DH
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-27-S12-29. PubMed ID: 9331116
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy.
Yoh K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Oct; 58(1):73-9. PubMed ID: 17548127
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
19. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
Ichiki M; Kawasaki M; Takayama K; Ninomiya K; Kuba M; Iwami F; Miyazaki N; Oishi K; Takeo S; Aizawa H; Nakanishi Y
Cancer Chemother Pharmacol; 2006 Sep; 58(3):368-73. PubMed ID: 16395589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
